A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Trial Profile

A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms CheckMate-004
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Nov 2017 Planned End Date changed from 30 Oct 2018 to 30 Dec 2019.
    • 30 Nov 2017 Planned primary completion date changed from 29 Oct 2017 to 7 Apr 2019.
    • 17 Oct 2017 Results (n=94) assessing updated survival, response, and safety data of nivolumab plus ipilimumab in patients with advanced melanoma,were published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top